Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team
Company Announcements

Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team

The latest announcement is out from Imunon ( (IMNN) ).

Imunon, Inc. has appointed Susan Eylward as its new General Counsel and Corporate Secretary, effective October 7, 2024, with a starting salary of $340,000 and eligibility for a 30% annual performance bonus. Eylward brings extensive experience in legal matters from her previous roles at companies like Science 37, Inc., Allstate Corporation, and National General Holdings Corp. To incentivize her employment, Imunon granted Eylward an option to purchase 50,000 shares of common stock, with a 10-year term and a four-year vesting schedule, under the Nasdaq Listing Rule 5635(c)(4). The company’s current projects include a DNA-based immunotherapy for ovarian cancer and a COVID-19 booster vaccine.

For a thorough assessment of IMNN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImunon, Inc. Reports Q3 2024 Earnings and Progress
TheFlyImunon presents data from Phase 2 OVATION 2 clinical trial
TheFlyImunon reports Q3 EPS (34c), consensus (40c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App